Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Fianlimab · REGN-3767

Monoclonal antibody · Antagonist of LAG-3 · developed by Regeneron Pharmaceuticals

Phase 1/2 Most advanced trial

1 Registered trials

What is Fianlimab?

Fianlimab is a human IgG4 monoclonal antibody that binds LAG-3 on tumor-infiltrating lymphocytes and blocks LAG-3 interaction with MHC class II molecules on antigen-presenting cells. This antagonism relieves T-cell suppression, enhancing antigen-specific T-cell activation and cytotoxic T-lymphocyte-mediated tumor cell killing. It is studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: REGN-3767
Drug type: Monoclonal antibody
Targets: LAG-3
Mechanism: Antagonist of LAG-3
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Regeneron Pharmaceuticals
In trials of: BMY
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: OX5LRQ5H6K

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04989946	Phase 1/2	Prostate Cancer	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

Other drugs acting on LAG3

Relatlimab FDA approved Favezelimab Phase 1/2 Tobemstomig Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z